and 5-HT2A receptor occupancy may represent a novel paradigm for developing innovative antipsychotics. The unique pharmacological features of 5i are a high affinity for dopamine D3, serotonin 5-HT1A and 5-HT2A receptors, together with a low affinity for dopamine D2 receptors (to minimize extrapyramidal side effects), serotonin 5-HT2C receptors (to reduce the risk of obesity under chronic treatment),
多巴胺D 3拮抗作用与5-羟
色胺5-HT 1A和5-HT 2A受体的结合可能代表了开发新型
抗精神病药的新范例。的独特的药理学特征5I是用于
多巴胺d的高亲和性3,
血清素5-HT 1A和5-HT 2A受体,连同对
多巴胺d具有低亲和力2个受体(以最小化锥体外系副作用),
血清素5-HT 2C受体(以减少在长期治疗下肥胖的风险)和hERG通道(以减少尖锐湿疣的发生率)。药理和生化数据,包括特定的c-fos在中皮层皮质区的表达,证实了体内5i的非典型抗精神病特征,其特征在于在抗精神病剂量下没有僵直症。